Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

Prostate cancer is a health issue that impacts individuals worldwide, and choosing the best treatment can be difficult, given ...

An analysis of four randomized controlled studies in patients with advanced prostate cancer who had received early vs. deferred ADT as primary therapy showed that early androgen suppression ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of international research on androgen deprivation therapy (ADT) for prostate cancer ...

The postsurgical combination of androgen deprivation therapy and Erleada has shown promising results in prostate cancer. Postsurgical treatment with androgen deprivation therapy and Erleada ...

Androgen-deprivation therapy (ADT) has become the mainstay of treatment for metastatic prostate cancer. ADT's testosterone depletion, however, leads to side effects that impair health-related ...

Two years of postsurgical androgen deprivation therapy resulted in a 10-year metastasis-free survival rate of nearly 80%. The addition of two years of androgen deprivation therapy (ADT) improved ...

New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients ...

This medication is a beneficial addition to your prostate cancer treatment plan — but it doesn’t come without risks. Here’s how to stay ahead of potential side effects. If you’ve been diagnosed with ...

The National Institute for Health and Care Excellence (NICE) has recommended a new oral hormone therapy for advanced hormone-sensitive prostate cancer. In final draft guidance, NICE said that more ...